|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
MXPA06001283A
(es)
*
|
2003-08-05 |
2006-04-11 |
Novo Nordisk As |
Derivados de insulina novedosos.
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
JP4808785B2
(ja)
|
2005-12-28 |
2011-11-02 |
ノボ・ノルデイスク・エー/エス |
インスリン組成物および組成物の製造方法
|
|
EP1991576B1
(en)
|
2006-02-27 |
2010-09-29 |
Novo Nordisk A/S |
Insulin derivatives
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
KR101452915B1
(ko)
|
2006-05-04 |
2014-10-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
다형태
|
|
US9034818B2
(en)
|
2007-06-13 |
2015-05-19 |
Novo Nordisk A/S |
Pharmaceutical formulations comprising an insulin derivative
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
CN102037008B
(zh)
|
2008-03-18 |
2016-08-31 |
诺沃-诺迪斯克有限公司 |
蛋白酶稳定化的、酰化胰岛素类似物
|
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
CA2736421A1
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
CN102256618A
(zh)
|
2008-10-17 |
2011-11-23 |
赛诺菲-安万特德国有限公司 |
胰岛素和glp-1激动剂的组合
|
|
AU2009309623B9
(en)
|
2008-10-30 |
2014-10-02 |
Novo Nordisk A/S |
Treating diabetes melitus using insulin injections with less than daily injection frequency
|
|
JP2012512848A
(ja)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
有機化合物の塩の形態
|
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
|
BRPI1008560B1
(pt)
|
2009-02-13 |
2021-08-31 |
Boehringer Ingelheim International Gmbh |
Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
|
|
PL2451437T3
(pl)
|
2009-07-06 |
2017-05-31 |
Sanofi-Aventis Deutschland Gmbh |
Wodne preparaty insuliny zawierające metioninę
|
|
NZ599847A
(en)
|
2009-11-13 |
2013-09-27 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
TR201809460T4
(tr)
|
2009-11-13 |
2018-07-23 |
Sanofi Aventis Deutschland |
Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
|
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
|
CA3070513C
(en)
|
2010-05-05 |
2023-01-03 |
Boehringer Ingelheim International Gmbh |
A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
AU2014203421B2
(en)
*
|
2010-05-19 |
2016-07-07 |
Sanofi |
Long-acting formulations of insulins
|
|
AU2012216648C1
(en)
*
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
KR20130093012A
(ko)
|
2010-06-24 |
2013-08-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
|
WO2012028172A1
(en)
|
2010-08-30 |
2012-03-08 |
Sanofi-Aventis Deutschland Gmbh |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
|
DK2632478T3
(da)
|
2010-10-27 |
2019-10-07 |
Novo Nordisk As |
Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
|
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
UA113626C2
(xx)
*
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
|
DK2731947T3
(en)
|
2011-07-15 |
2019-04-23 |
Boehringer Ingelheim Int |
SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
|
|
JP5950477B2
(ja)
|
2011-08-10 |
2016-07-13 |
アドシア |
少なくとも1種の基礎インスリンの注射溶液
|
|
FR2984749A1
(fr)
*
|
2011-12-23 |
2013-06-28 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique
|
|
AR087693A1
(es)
|
2011-08-29 |
2014-04-09 |
Sanofi Aventis Deutschland |
Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
FR2985428B1
(fr)
*
|
2012-01-09 |
2016-05-27 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
|
|
WO2013104861A1
(fr)
|
2012-01-09 |
2013-07-18 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
|
|
FR2985429B1
(fr)
*
|
2012-01-09 |
2016-07-29 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
|
WO2013171166A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
FR3001896B1
(fr)
|
2013-02-12 |
2015-07-03 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
|
|
US20150314003A2
(en)
|
2012-08-09 |
2015-11-05 |
Adocia |
Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
FR3001895B1
(fr)
*
|
2013-02-12 |
2015-07-03 |
Adocia |
Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
|
|
HK1211232A1
(en)
|
2012-12-21 |
2016-05-20 |
Sanofi |
Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
|
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
|
EP2983697B1
(en)
|
2013-04-03 |
2018-10-31 |
Sanofi |
Treatment of diabetes mellitus by long acting formulations of insulins
|
|
JP2016519127A
(ja)
*
|
2013-04-30 |
2016-06-30 |
ノヴォ ノルディスク アー/エス |
新規投与レジメン
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/gip受體促效劑
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
US9895423B2
(en)
|
2014-01-09 |
2018-02-20 |
Sanofi |
Stabilized pharmaceutical formulations of insulin aspart
|
|
JP6723921B2
(ja)
|
2014-01-09 |
2020-07-15 |
サノフイSanofi |
インスリンアナログおよび/またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
|
|
CN105960249B
(zh)
|
2014-01-09 |
2021-03-16 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
|
|
EP3098235A4
(en)
|
2014-01-20 |
2017-10-18 |
Hanmi Pharm. Co., Ltd. |
Long-acting insulin and use thereof
|
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
|
AR099569A1
(es)
|
2014-02-28 |
2016-08-03 |
Novo Nordisk As |
Derivados de insulina y los usos médicos de estos
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
|
AR100639A1
(es)
*
|
2014-05-29 |
2016-10-19 |
Hanmi Pharm Ind Co Ltd |
Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
|
|
TWI684458B
(zh)
|
2014-05-30 |
2020-02-11 |
南韓商韓美藥品股份有限公司 |
包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
PE20171622A1
(es)
|
2014-12-12 |
2017-11-02 |
Sanofi Aventis Deutschland |
Formulacion de relacion fija de insulina glargina/lixisenatida
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
|
UY36870A
(es)
|
2015-08-28 |
2017-03-31 |
Hanmi Pharm Ind Co Ltd |
Análogos de insulina novedosos
|
|
EP3359555B1
(en)
|
2015-10-07 |
2023-12-20 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens
|
|
EP4233840A3
(en)
|
2016-06-10 |
2023-10-18 |
Boehringer Ingelheim International GmbH |
Combinations of linagliptin and metformin
|
|
WO2018055539A1
(en)
*
|
2016-09-22 |
2018-03-29 |
Wockhardt Limited |
Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
|
|
RU2764197C1
(ru)
|
2016-09-23 |
2022-01-14 |
Ханми Фарм. Ко., Лтд. |
Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
|
|
TWI700091B
(zh)
|
2016-12-16 |
2020-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
含胰島素醫藥組成物
|
|
AR111341A1
(es)
|
2017-03-23 |
2019-07-03 |
Hanmi Pharm Ind Co Ltd |
Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
|
|
JP2020516607A
(ja)
|
2017-04-07 |
2020-06-11 |
アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. |
投与レジメンならびに関連組成物および方法
|
|
AU2018386304B2
(en)
|
2017-12-15 |
2023-12-07 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens and related compositions and methods
|
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
|
US12343383B2
(en)
|
2019-07-12 |
2025-07-01 |
Novo Nordisk A/S |
High concentration insulin formulation
|
|
CN110669680A
(zh)
*
|
2019-11-04 |
2020-01-10 |
张少清 |
黑酵母菌的培养方法及从黑酵母菌中提取β葡聚糖的工艺
|
|
WO2021105393A1
(en)
|
2019-11-29 |
2021-06-03 |
Novo Nordisk A/S |
Processes for obtaining stable glp-1 compositions
|
|
WO2021142733A1
(en)
*
|
2020-01-16 |
2021-07-22 |
Shanghai Benemae Pharmaceutical Corporation |
Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
|
|
EP4090351B1
(en)
*
|
2020-01-16 |
2026-03-04 |
Shanghai Benemae Pharmaceutical Corporation |
Dosing regimen of glp-1
|
|
WO2022034062A1
(en)
*
|
2020-08-12 |
2022-02-17 |
Txp Pharma Ag |
Exendin-4 peptide analogues
|
|
JP2024522904A
(ja)
*
|
2021-06-25 |
2024-06-21 |
ガン アンド リー ファーマシューティカルズ カンパニー リミテッド |
アシル化インスリンを含む医薬組成物
|
|
EP4180060A1
(en)
|
2021-11-15 |
2023-05-17 |
Adocia |
Solid compositions comprising a peptide or a protein and an acylated amino acid
|
|
EP4299057A1
(en)
|
2022-06-30 |
2024-01-03 |
Adocia |
Solid compositions comprising a peptide or a protein and an acylated amino acid
|
|
US20250000948A1
(en)
|
2021-11-15 |
2025-01-02 |
Adocia |
Solid compositions comprising a peptide or a protein and an acylated amino acid
|
|
EP4299071A1
(en)
|
2022-07-01 |
2024-01-03 |
Adocia |
Compositions comprising a peptide or a protein and an acylated amino acid
|